Frequencies of CYP3A5*1/*3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 6, 2012, Pages 644-647

  Elmachad, Mustapha ^a,b   Elkabbaj, Driss ^c   Elkerch, Fatiha ^b   Laarabi, Fatima Zahra ^b   Barkat, Amina ^d   Oualim, Zouhir ^c   Sefiani, Abdelaziz ^a,b  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b INSTITUT NATIONAL D HYGIÈNE   (Morocco)

^c MILITARY HOSPITAL MOHAMMED V   (Morocco)

^d Centre National de Reference en Neonatologie et en Nutrition   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MOROCCO; NEUROPATHY; WILD TYPE; DOSE RESPONSE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEGRO; NEWBORN; PHARMACOGENETICS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MOROCCO; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TACROLIMUS; YOUNG ADULT;

EID: 84862994381     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0240     Document Type: Article

References (20)

1. Balram C, Zhou Q, Cheung YB, Lee EJ (2003) CYP3A5*3 and*6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 59:123-126. (Pubitemid 36793724)
2. Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-439.
3. Dally H, Bartsch H, Jager B, et al. (2004) Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett 207:95-99. (Pubitemid 38429891)
4. Floyd MD, Gervasini G, Masica AL, et al. (2003) Genotypephenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606. (Pubitemid 37311146)
5. Fukuen S, Fukuda T, Maune H, et al. (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics 12:331-334. (Pubitemid 34620661)
6. Haufroid V, Mourad M, Van Kerckhove V, et al. (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154. (Pubitemid 38373108)
7. Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349. (Pubitemid 29366813)
8. Kudzi W, Dodoo AN, Mills JJ (2010) Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 11:111.
9. Kuehl P, Zhang J, Lin Y, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. (Pubitemid 32268418)
10. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294. (Pubitemid 35284253)
11. Lin YS, Dowling AL, Quigley SD, et al. (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172. (Pubitemid 34680528)
12. Macphee IA, Fredericks S, Mohamed M, et al. (2005) Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79:499-502. (Pubitemid 40280186)
13. Murray GI, McFadyen MC, Mitchell RT, et al. (1999) Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1836-1842. (Pubitemid 29132313)
14. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162. (Pubitemid 35246494)
15. Paine MF, Hart HL, Ludington SS, et al. (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
16. Quteineh L, Verstuyft C, Furlan V, et al. (2008) Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 103:546-552.
17. Sinues B, Vicente J, Fanlo A, et al. (2007) CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit 29:412-416. (Pubitemid 47220457)
18. Thervet E, Anglicheau D, King B, et al. (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235. (Pubitemid 37339651)
19. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. (2004) CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 75:1059-1069. (Pubitemid 39534403)
20. Tsuchiya N, Satoh S, Tada H, et al. (2004) Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78:1182-1187. (Pubitemid 39426437)